Abstract
Structure and function are intimately related. Nowhere is this more important than the area of bioactive molecules. It has been shown that the enantioselectivity of an enzyme is directly related to its chirality. X-ray crystallography is the only method for determining the “absolute” configuration of a molecule and is the most comprehensive technique available to determine the structure of any molecule at atomic resolution. Results from crystallographic studies provide unambiguous, accurate, and reliable 3-dimensional structural parameters, which are prerequisites for rational drug design and structure-based functional studies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Griffin JF, Duax WL, eds. Molecular Structure and Biological Activity. New York, NY: Elsevier Biomedical; 1982.
Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of 2 related pentapeptides from brain with potent opiate agonist activity. Nature. 1975;258:577-579.
Temussi PA, Picone D, Castiglione-Morelli MA, Motta A, Tancredi T. Bioactive conformation of linear peptides in solution: an elusive goal. Biopolymers. 1989;28:91-107.
Karle IL, Karle J, Mastropaolo D, Camerman A, Camerman N. [Leu - 5 ]enkepalin -4 co-crystallizing conformers with extended backbones that form an anti-parallel beta-sheet. Acta Crystallogr. 1983;B39:625-637.
Smith D, Griffin JF. Conformation of [Leu-5]enkephalin rrom X-ray-diffraction: features important for recognition at opiate receptor. Science. 1978;199:1214-1216.
Aubry A, Birlirakis N, Sakarellos-Daitsiotis M, Sakarellos C, Marraud M. A crystal molecular-conformation of leucine-enkephalin related to the morphine molecule. Biopolymers. 1989;28:27-40.
Doi M, Tanaka M, Ishida T, et al. Crystal-structures of [Met5] and [(4-bromo)Phe4,Met5]e nkephalins: formation of a dimeric antiparallel beta-structure. J Biochem (Tokyo). 1987;101:485-490.
Loew GH. Molecular modeling of opioid analgesics. Mod Drug Discovery. 1999;2:24-30.
SHELXTL [Computer program]. Version 6.10. Madison, Wisconsin: Bruker AXS Inc. 2000.
Griffin JF, Langs DA, Smith GD, Blundell TL, Tickle IJ, Bedarkar S. The crystal-structures of [Met5] enkephalin and a third form of [Leu5] enkephalin: observations of a novel pleated β-sheet. Proc Natl Acad Sci USA. 1986;83:3272-3276.
Deschamps JR, Flippen-Anderson JL, Brine GA, Hayes JP, George C. Boc-tyrosyl-D-alanyl-glycyl-N-methyl-pnenylalanyl-O-methyl-methionine hydrate: a protected analog of metkeph-amid. Acta Crystallogr. 2002;58E:o13-o15.
Ishida T, Kenmotsu M, Mino Y, et al. X-Ray diffraction studies of enkephalins: crystal-structure of [(4′-bromo)Phe4,Leu5] enkephalin. Biochem J. 1984;218:677-689.
Stezowski JJ, Eckle E, Bajusz SA. Crystal-structure determination for Tyr-d-Nle-Gly-Phe-Nles [Nles=MetCH2CH2CH2CH(NH2)SO3H]: an active synthetic enkephalin analog. J Chem Soc Chem Comm. 1985;11:681-682.
Deschamps JR, George C, Flippen-Anderson JL. [D-Ala2,D-Leu5]-enkephalin (DADLE). Acta Crystallogr. 1996;52:1583-1585.
Flippen-Anderson JL, Deschamps JR, Ward KB, George C, Houghten R. The crystal structure of deltakephalin: a δ-selective opioid peptide with a novel β-bend-like conformation. Int J Pept Protein Res. 1994;44:97-104.
Fournie-Zaluski M, Prange T, Pascard C, Roques BP. Enkephalin related fragments: conforma-tional studies of the tetrapeptides Tyr-Gly-Gly-Phe and Gly-Gly-Phe-X (X = Leu, Met) by X-ray and 1H NMR spectroscopy. Biochem Biophys Res Commun. 1977;79:1199-1206.
Flippen-Anderson JL, Deschamps JR, George C, Hruby VJ, Misicka A, Lipkowski AW. Crystal structure of biphalin - multireceptor opioid peptide. J Pept Res. 2002;59:123-133.
Flippen-Anderson JL, George C, Deschamps JR, Reddy PA, Lewin AH, Brine GA. X-ray structures of a potent δ-receptor selective opioid antagonist and a protected form of the δ-receptor antagonist ICI 174,864. Lett Pept Sci. 1994;1:107-115.
Flippen-Anderson JL, Hruby VJ, Collins N, George C, Cudney B. X-ray structure of [D-Pen2,D-Pen5]enkephalin, a highly potent, delta-opioid receptor-selective compound: com-parisons with proposed solution conformations. J Am Chem Soc. 1994;116:7523-7531.
Collins N, Flippen-Anderson JL, Haaseth R, et al. Conformational determinants of agonist versus antagonist properties of [D-Pen2,D-Pen5]-enkephalin (DPDPE) analogs at opioid recep-tors: comparison of x-ray crystallographic structure, solution 1H NMR data, and molecular dynamic simulations of [L-Ala3]DPDPE and [D-Ala3]DPDPE. J Am Chem Soc. 1996;118:2143-2152.
Nikiforovich GV, Kover KE, Kolodziej SA, et al. Design and comprehensive conformational studies of Tyr1-cyclo(D-Pen2-Gly3-Phe5-l-3-Mpt5) and Tyr(1)-cyclo(Pen2-Gly3-Phe5-d-3-Mpt5): novel conformationally constrained opioid peptides. J Am Chem Soc. 1996;118:959-969.
Lomize AL, Flippen-Anderson JL, George C, Mosberg HI. Conformational-analysis of the delta-receptor-selective, cyclic opioid peptide, Tyr-cyclo[D-Cys-Phe-D-Pen]OH (JOM-13): comparison of X-ray crystallographic structures, molecular mechanics simulation, and 1H-NMR data. J Am Chem Soc. 1994;116:429-436.
Flippen-Anderson JL, Deschamps JR, George C, et al. X-ray structure of Tyr-D-Tic-Phe-Phe-NH2 (D-TIPP-NH2), a highly potent µ-receptor selective opioid agonist: comparisons with proposed model structures. J Pept Res. 1997;49:384-393.
Ciajolo MR, Balboni G, Picone D, et al. A solution and solid-state structure of the diketopi-perazine of tyrosyl-tetrahydroisoquinoline-3-carboxylic acid. Int J Pept Protein Res. 1995;46:134-138.
Deschamps JR, Flippen-Anderson JL, George C. 2-[N-(t-Butoxycarbonyl)tyrosyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid nitromethane solvate. Acta Crystallogr. 2001;57E: o87-o90.
Deschamps JR, Flippen-Anderson JL, Moore C, Cudney R, George C. Tyrosyl-D-tetrahydroi-soquinoline-3-carboxylic acid and tyrosyl-D-tetrahydroisoquinoline-3-carboxamide. Acta Crystallogr. 1997;C53:1478-1482.
Bryant SD, George C, Flippen-Anderson JL, et al. Crystal structures of dipeptides containing the DMT-TIC pharmacophore. J Med Chem. 2002;45:5506-5513.
Petsko GA. On the other hand.… Science. 1992;256:1403-1404.
Milton RC, Milton SCF, Kent BBH. Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show demonstration of reciprocal chiral substrate specificity. Science. 1992;256:1445-1448.
Coster D, Knol KS, Prins JA. Unterschiede in der intensität der röntgenstrahlen-feflexion an den beiden 111-flächen der zinkblende. Z Phys. 1930;63:345-369.
Bijvoet JM, Peerdeman AF, van Bommel AJ. Determination of the absolute configuration of optically active compounds by means of X-rays. Nature. 1951;168:271-272.
Flack HD. On enantiomorph-polarity estimation. Acta Crystallogr. 1983;A39:876-881.
Schiller PW, Nguyen TMD, Weltrowska G, et al. Differential stereochemical requirments of µ vs δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc Natl Acad Sci USA. 1992;89:11871-11875.
Balboni G, Guerrini R, Salvadori S, et al. Evaluation of the Dmt-Tic pharmacophore: conver-sion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties. J Med Chem. 2002;45:713-720.
Eddy NB, May EL. The search for a better analgesic. Science. 1973;181:407-414.
Schiller PW, Yam CF, Lis M. Evidence of topographical analogy between methionine-enkephalin and morphine derivatives. Biochemistry. 1977;16:1831-1838.
Gylbert L. The crystal and molecule structure of morphine hydrochloride trihydrate. Acta Crystallogr. 1973;B29:1630-1635.
Thomas G. Medicinal Chemistry: An Introduction. Chichester, UK: John Wiley & Sons; 2000.
Foye WO, Lemke TL, Williams DA. Principles of Medicinal Chemistry. Baltimore, MD: Williams & Wilkins; 1995.
Michel AG, Evrard G, Norberg B, Milchert E. Molecular-Structure of Opiate Alkaloids. 2. Crystal-Structures of4-Methylhomobenzomorphan Hydrobromide(I) and4,12-beta- Dimethylhomobenzomorphan (II). Can J Chem. 1988;66:1763-1769.
Thomas JB, Zheng XL, Mascarella SW, et al. N-substituted 9β-methyl-5-(3-hyroxyphenyl)morphans are opioid receptor pure antagonists. J Med Chem. 1998;41:4143-4149.
Hashimoto A, Jabobson AE, Rothman RB, et al. Probes for narcotic receptor mediated phe-nomena. 28. New opioid antagonists from enantiomeric analogues of m-hydroxyphenyl-N-phenylethylmorphan. Bioorg Med Chem. 2002;10:3319-3329.
Flippen-Anderson JL, George C, Bertha CM, Rice KC. X-ray crystal structures of potent opi-oid receptor ligands: etonitazene, cis-(+)-3-methylfentanyl, etorphine, diprenorphine, and buprenorphine. Heterocycles. 1994;39:751-766.
Hruby VJ, Gehrig CA. Recent developments in the design of receptor specifico-peptides. Med Res Rev. 1989;9:343-401.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Deschamps, J.R. (2008). The Role of Crystallography in Drug Design. In: Rapaka, R.S., Sadée, W. (eds) Drug Addiction. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76678-2_21
Download citation
DOI: https://doi.org/10.1007/978-0-387-76678-2_21
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-76677-5
Online ISBN: 978-0-387-76678-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)